When developing topical and transdermal generic drug products, overlooking Q1, Q2, and Q3 alignment early in development can result in regulatory deficiency letters, repeat IVPT studies, or the need for costly clinical endpoint trials. This is why Q1/Q2/Q3 strategies are foundational. These classification tiers, Q1 (Qualitative Sameness), Q2 (Quantitative Sameness), and Q3 (Structural and Physicochemical […]